BSC
VRDN icon

BOLTON SECURITIES CORPORATION’s Viridian Therapeutics VRDN Stock Holding History

BOLTON SECURITIES CORPORATION’s Portfolio VRDN Stock Details VRDN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$206K Hold
10,000
– – 0.01% 881
2026
Q2 		$184K Buy
+10,000
New +$161K 0.01% 923

Other funds holding VRDN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return
Candriam SCA
Candriam SCA Strassen, Luxembourg, Luxembourg $22.5B AUM 50.38% 1-Year Est. Return
BNP Paribas Financial Markets
BNP Paribas Financial Markets Paris, France $294B AUM 47.59% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.84T AUM 33.86% 1-Year Est. Return
Davern Capital Partners
Davern Capital Partners Ny, New York $514M AUM 16.9% 1-Year Est. Return
Emerald Advisers
Emerald Advisers Leola, Pennsylvania $3.64B AUM 71.19% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return

BOLTON SECURITIES CORPORATION's VRDN Position: Q3 2026 in Review

BOLTON SECURITIES CORPORATION held its Viridian Therapeutics (VRDN) position steady in Q3 2026 at 10,000 shares worth $206K. The position accounts for 0.01% of the portfolio, ranked #881.

BOLTON SECURITIES CORPORATION first reported a position in VRDN in Q2 2026 and has held it in 2 quarters since. 115 funds tracked by Wall St. Rank hold VRDN as of Q3 2026.

  • BOLTON SECURITIES CORPORATION held 10,000 shares of Viridian Therapeutics worth $206K as of Q3 2026.
  • BOLTON SECURITIES CORPORATION left its Viridian Therapeutics share count unchanged in Q3 2026.
  • Viridian Therapeutics made up 0.01% of BOLTON SECURITIES CORPORATION's portfolio in Q3 2026, its #881 holding.
  • BOLTON SECURITIES CORPORATION first reported a position in Viridian Therapeutics in Q2 2026 and has held it in 2 quarters since.
  • 115 funds tracked by Wall St. Rank held Viridian Therapeutics as of Q3 2026.

Based on BOLTON SECURITIES CORPORATION's 13F filing for Q3 2026, filed 12 Nov 2026.